Publications by authors named "Scott Monk"

Claim this Profile
R
Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species.
Brian A Willis, Stephen L Lowe, Scott A Monk, Patrick J Cocke, Christopher D Aluise

J Alzheimers Dis Rep· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
David L McKinzie, Leonard L Winneroski, Steven J Green, Erik J Hembre, Jon A Erickson, Scott A Monk

J Med Chem· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Excretion, Mass Balance, and Metabolism of [C]LY3202626 in Humans: An Interplay of Microbial Reduction, Reabsorption, and Aldehyde Oxidase Oxidation That Leads to an Extended Excretion Profile.
Kishore Katyayan, Ping Yi, Scott Monk, Kenneth Cassidy

Drug Metab Dispos· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etexilate, a Prototypical P-gp Substrate.
Scott A Monk, Alan R Kugler, Scott W Andersen, Mosun A Ayan-Oshodi, Douglas E James

J Clin Pharmacol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
Brian A Willis, Scott W Andersen, Mosun Ayan-Oshodi, Douglas E James, Emily Liffick, Scott A Monk

J Clin Pharmacol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints.
Leonard L Winneroski, Jon A Erickson, Steven J Green, Jose E Lopez, Stephanie L Stout, Scott A Monk

Bioorg Med Chem· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics.
Naidong Ye, Scott A Monk, Pankaj Daga, David M Bender, Laura B Rosen

Clin Pharmacol Drug Dev· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous quantitation of the BACE1 inhibitor AZD3293 and its metabolite AZ13569724 in human matrices by LC-MS/MS.
Yan Li, Paul H Severin, Mark R Hoffmann, Dennis L Miller, Scott A Monk

Bioanalysis· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Model for Single Neuron Activity With Refractory Effects and Spike Rate Estimation Techniques.
Scott Monk, Harry Leib

IEEE Trans Neural Syst Rehabil Eng· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preparation and biological evaluation of conformationally constrained BACE1 inhibitors.
Leonard L Winneroski, Matthew A Schiffler, Jon A Erickson, Patrick C May, Scott A Monk

Bioorg Med Chem· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans.
Patrick C May, Brian A Willis, Stephen L Lowe, Robert A Dean, Scott A Monk

J Neurosci· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.
Patrick C May, Robert A Dean, Stephen L Lowe, Ferenc Martenyi, Scott M Sheehan, Scott A Monk

J Neurosci· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reversible stepwise negative regulation of CYP1A1 in cultured rat epidermal cells.
Scott A Monk, Michael S Denison, Robert H Rice

Arch Biochem Biophys· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis